Duol Mulsan, Changes Company Name to 'Canaria Bio'..."Focusing on Bio Power"

[Asia Economy Reporter Hyunseok Yoo] Duol Mulsan announced on the 29th that it has changed its company name to Canariabio (English name CANARIABIO Inc.) and will focus on the bio business. The company held an extraordinary general meeting of shareholders on the 28th and approved the partial amendment of the articles of incorporation (company name change).

Canariabio is a specialized company in anticancer drug development and has acquired assets for the development of immuno-oncology drugs through its affiliates. Through additional business restructuring, it plans to carry out various immuno-oncology drug development projects targeting ovarian cancer, pancreatic cancer, and metastatic breast cancer.

The core pipeline, the ovarian cancer treatment drug ‘Oregobomab,’ began global Phase 3 clinical trials last year. According to the results of the previous Phase 2 trial, progression-free survival increased by 30 months compared to the existing treatment (control group), drawing attention through a world-renowned journal related to gynecologic cancers. Currently, clinical sites are open in 11 countries worldwide, with 119 clinical sites recruiting patients. The company plans to recruit 602 patients by next year.

Nahanik, CEO of Canariabio, said, “The canary bird symbolizes joy and peace,” and explained, “This company name change reflects not only the realization of the company’s dream of ‘life extension’ but also the determination to continuously develop immuno-oncology drugs that can improve the quality of life and provide peace to patients.” He added, “We will do our best to create new hope not only for patients suffering from cancer but also for their families through innovative anticancer drugs.”

This content was produced with the assistance of AI translation services.